References

1. Brinton RD, Tran J, Proffitt P, Kahil M. 17ß-estradiol increases the growth and survival of cultured cortical neurons. Neurochemical Res. 1997;22:1339-1351.

2. Brinton RD, Proffitt P, Tran J, Luu R. Equilin, a principal component of the estrogen replacement therapy Premarin, increases the growth of cortical neurons via an NMDA receptor-dependent mechanism. Exp Neurol. 1997;147:211-220.

3. Matsumoto A, Arai Y, Osanai M. Estrogen stimulates neuronal plasticity in the deafferented hypothalamic arcuate nucleus in aged female rats. Neurosci Res. 1985;2:412418.

4. Okhura T, Teshima Y, Isse K, et al. Estrogen increases cerebral and cerebellar blood flow in postmenopausal women. Menopause. 1995;2:13-18.

5. Simpkins JW. Presentation, Society for Neuroscience. 1995. Los Angeles.

6. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res. 1994;644:305-312.

7. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger hippocampal brain expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology. 1996;136:2320-2324.

8. Sherwin BB. Impact of the changing hormonal milieu on psychological functioning. In: Lobo RE, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York, NY: Raven Press; 1994:119-127.

9. Phillips S, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485-495.

10. Jacobs DM, Tang M-X, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50:368-373.

11. Rousseau ME. Women's midlife health: reframing menopause. J Nurse Midwifery. 1998;43(3):208-223.

12. Smith RNJ, Studd JWW. Estrogens and depression in women. In: Lobo RE, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York, NY: Raven Press; 1994:129-136.

13. Archer JSM. Relationship between estrogen, serotonin, and depression. Menopause. 1999;6:71-78.

14. Joffe H, Cohen LS, Hennen J, Carlson K. The perimenopause is a period of risk for depressive symptoms in middle-aged women [NR 13]. The American Psychiatric Association 152nd Annual Meeting, Washington DC, May 1999.

15. Stahl SM. Augmentation of antidepressants by estrogen. Psychopharmacol Bull. 1998;34:319-321.

16. Halbreich U. Role of estrogen in postmenopausal depression. Neurology. 1997;48(suppl 7):S16-S20.

17. Evans DA, Scherr PA, Cook NR, et al. Estimated prevalence of Alzheimer's disease in the United States. Milbank Mem Fund Q. 1990;68:267-289.

18. Mölsä PK, Marttila RJ, Rinne UK. Epidemiology of dementia in a Finnish population. Acta Neurol Scand. 1982;65:541-552.

19. Herbert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995;273:1354-1359.

20. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 1987;76:465-479.

21. Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in "Anormal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46:707-719.

22. Aronson MS, Ooi WL, Morgenstern H, et al. Women, myocardial infarction, and dementia in the very old. Neurology. 1990;40:1102-1106.

23. Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB. Postmenopausal estrogen replacement therapy on the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994;140:262-267.

24. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med. 1996;156:2213-2217.

25. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1521.

26. Tang M-X, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.

27. Lerner AJ, Koss E, Debanne SM, et al. Interactions of smoking history with estrogen replacement therapy as protective factors for Alzheimer's disease. Presentation, 26th Annual Meeting, Society of Neuroscience, Washington, DC. 1996.

28. Caldwell BM. An evaluation of psychological effects of sex hormone administration in aged women. J Gerontol. 1954;9:168-174.

29. Kantor HI, Michael CM, Shore H. Estrogen for older women Am J Obstet Gynecol. 1973;116:115-118.

30. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino. Low-dose estrogen replacement therapy for Alzheimer's disease in women. Menopause. 1994;1:125-130.

31. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 1996;46:1580-1584.

32. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology. 1997;48(suppl 7):S36-S41.

33. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology.1992;17:485-495.

34. Raloxifene [package insert]. Indianapolis, Ind: Eli Lilly and Company; 1998.

35. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.

36. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.

37. Sano M, Ernesto C, Thomas RG, et al. A controlled rial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease. Engl J Med. 1997;336:1216-1222.

38. Speck, CE, Kukull WA. History of depression as a risk factor for Alzheimer's disease. Epidemiology. 1995;6:366-369.

39. Fitz, AG, Teri L. Depression, cognition, and functional ability in patients with Alzheimer's disease.J Am Geriatr Soc. 1994;42:186-191.

40. Schindler RJ. Behavioral problems in Alzheimer's disease: Introduction affective disorders, neurovegatative syndromes, and general principles of pharmacotherapy. Proceedings of the American Academy of Neurology 51st Annual Meeting. Toronto, Canada.1999.

41. Folstein M, Bylsma F. Noncognitive symptoms of Alzheimer's disease. In: Terry RD, Katzman R, Sisodia SS, Bick KL, ed.Alzheimer's Disease, 2nd ed. Philadelphia: Lippincott, Williams, & Wilkins; 1999;25-36.

42. Fischer P, Simanyi M, Danielczyk W. Depression in dementia of the Alzheimer's type and in multi-infarct dementia. Am J Psychiatry. 1990;147:1484-1487.

43. Donaldson C, Burns A. Burden of Alzheimer's disease; helping the patient and caregiver. J Geriatr Psychiatry Neurol. 1999;12(1):21-28.

44. Sparks MB, Farran CJ, Donner E, Keane-Hagerty E. Wives, husbands, and daughters of dementia patients: predictors of caregivers' mental and physical health. Sch Inq Nurs Pract. 1999;12:221-234; discussion 235-238.

45. Buckwalter KC, Gerdner L, Kohout F, Hall GR, Kelly A, Richards B, Sime M. A nursing intervention to decrease depression in family caregivers of persons with dementia. Arch Psychiatr Nurs. 1999:13(2):80-88.

46. Chou KR, LaMontagne LL, Hepworth JT. Burden experienced by caregivers of relatives with dementia in Taiwan. Nurs Res 1999;48(4):206-214.

47. Leblanc AJ, London AS, Aneshensel CS. The physical cost of AIDS caregiving. Soc Sci Med. 1997;45:916-923.

48. Knop DS, Bergman-Evans B, McCabe BW. In sickness and in health: an exploration of the perceived quality of the marital relationship, coping, and depression in caregivers of spouses with Alzheimer's disease. J Psychosoc Nurs Ment Health Serv. 1998;36:16-21.

49. Goode KT, Haley WE, Roth DL, Ford GR. Predicting longitudinal changes in caregiver physical and mental health: a stress process model. Health Psychol. 1998;17:190-198.

50. Yates ME, Tennstedt S, Chang BH. Contributors to and mediators of psychological well-being for informal caregivers. J Gerontol B Psychol Sci Soc Sci. 1999;54(1):P1-P22.

51. Robinson K, Austion JK. Wife caregivers' and supportive others' perceptions of the caregivers' health and social support. Res Nurs Health. 1998;21(1):51-57.

52. National Cancer Institutes. Cancer incidence in the United States (SEER), 1987-1991. Available at http://rex.nc.nih.giv/NCI_Pub_interface/raterisk/rates12.html. Accessed November 13, 1999.

53. American Cancer Society. Available at: http://www.cancer.org/statistics/cff98/selectedcancers.html. Accessed May 5, 1998.

54. Calle EE. Hormone replacement therapy and colorectal cancer: interpreting the evidence. Cancer Causes Control. 1997;8:127-129.

55. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:74-79.

56. Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA). Cancer Causes Control. 1994;5:359-366.

57. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87:517-523.

58. Sturgeon SR, Schairer C, Brinton LA, et al. Evidence of a healthy estrogen user survivor effect. Epidemiol. 1995;6:227-231.

59. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst. 1995;87:1067-1071.

60. Folsom AR, Mink PJ, Sellers TA, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Pub Health. 1995;85:1128-1132.

61. Troisi R, Schairer C, Chow W-H, et al. A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes and Control. 1997;8:130-138.

62. Kampman E, Porter JD, Slattery ML, et al. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes and Control. 1997;8:146-158.

63. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998;128:705-712, 1998.

64. Paganini-Hill A. Estrogen replacement therapy and colorectal cancer risk in elderly women. Dis Colon Rectum. In press.

65. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol. 1999. In press.

66. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574-582.

67. Metka M, Enzelsberger H, Knogler W, Schurz B, Aichmar H. Ophthalmic complaints as a climacteric symptom. Maturitas. 1991;14:3-8.

68. The Eye-Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 1992;110:1701-1708.

69. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.

70. Vingerling JR, Dielemans I, Witteman CM, Hofman A, Grobbee DE, de Jong TVM. Macular degeneration and early menopause: a case-control study. Br Med J. 1995;310:1570-1571.

71. Klein BE, Klein R, Jensen SC, Ritter LL. Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 1994;92:289-295.

72. Lang AE, Lozano AM. Parkinson's disease. First of two parts. Engl J Med. 1998;339:1044-1053.

73. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. Engl J Med. 1998;339:1130-1143.

74. Weiner WJ, Lang AE. Movement Disorders: A Comprehensive Survey. Mt Kisco, NY: Futura Publishing Company; 1989.

75. Watts RL, Koller WC, eds. Movement Disorder: Neurologic Principles and Practice. New York, NY: McGraw-Hill; 1997.

76. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984;16:278-282.

77. Bazzett TJ, Becker JB. Sex differences in the rapid and acute effects of estrogen on striated D2 dopamine receptor binding. Brain Res. 1994;637:163-172.

78. Disshon KA, Dluzen DE. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release. Brain Res. 1997;764:9-16.

79. Disshon KA, Boja JW, Dluzen DE. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur J Pharmacol. 1998;345:207-211.

80. Morissette M, Garcia-Segura LM, Belanger A, Di Paolo T. Changes of rat striatal neuronal membrane morphology and steroid content during the estrous cycle. Neuroscience. 1992;49:893-902.

81. McDermott JL, Liu B, Dluzen DE. Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol. 1994;125:306-311.

82. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Transdermal 17(ß-estradiol in postmenopausal parkinsonian patients. Mov Disord. 1998;13(suppl 2):257. Abstract.

83. Tao X, Shu-Leong H, Ramsden D. Estrogen can down-regulate the human catechol-O-methyltransferase gene expression: its implication in Parkinson's disease. Mov Disord. 1998;13(suppl 2):114. Abstract.

84. Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Pramipexole and levodopa pharmacokinetics following concomitant administration. Neurology. 1997;48:185.

85. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990;40:763-766.

86. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39:37-45.

87. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology. 1999;52:1417-1421.

88. Thulin PC, O'Brien SA, Filoteo JV, Roberts JW. Effect of estrogen replacement therapy on memory in women with Parkinson's disease. Mov Disord. 1998;13(suppl 2):56. Abstract.

89. Marder K, Tang M-X, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology. 1998;50:1141-1143.

90. Diabetes Facts and Figures. American Diabetes Association Web site. Available at: http://www.diabetes.org/ada/c20f.asp. Accessed January 1, 1999.

91. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women. Circulation. 1993;88:1999-2009.

92. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb. 1992;12:647-656.

93. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.

94. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA. 1991;265:627-631.

95. Warram JH, Kopczynski J, Janka HU, Krolewski AS. Epidemiology of non-insulin-dependent diabetes mellitus and its macrovascular complications. Endocrinol Metab Clin North Am. 1997;26:165-188.

96. Kaplan RC, Heckbert SR, Weiss NS, et al. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care. 1998;21:1117-1121.

97. Friday KE, Dong C, Fontenot RU. Estrogen replacement therapy improves glycemic control and plasma lipoproteins but increases fasting triglyceride in postmenopausal type 2 diabetic women. Presented at: Annual Session of the American Diabetes Association; June 1998; Chicago.

98. Nevitt MC, Cummings SR, Lane NE, et al. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1996;156:2073-2080.